Provided by Tiger Trade Technology Pte. Ltd.

SIMCERE PHARMA

12.150
+0.0200.16%
Volume:6.74M
Turnover:81.39M
Market Cap:31.54B
PE:41.64
High:12.240
Open:12.060
Low:11.900
Close:12.130
52wk High:15.080
52wk Low:6.099
Shares:2.60B
HK Float Shares:2.60B
Volume Ratio:1.25
T/O Rate:0.26%
Dividend:0.17
Dividend Rate:1.44%
EPS(LYR):0.292
ROE:12.45%
ROA:6.50%
PB:3.90
PE(LYR):41.64
PS:3.97

Loading ...

BOCOM INTL: China's 1st-8th Batch National Drug Procurement Renewal Rules Likely Moderate, Short-Term Catalysts Ample

Stock News
·
Dec 05, 2025

10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled

Stock News
·
Dec 03, 2025

Simcere (2096) Enters Exclusive Licensing with Vigonvita (2630.HK) for Deuterated Remdesivir Hydrobromide

Bulletin Express
·
Dec 03, 2025

VIGONVITA-B (02630) Signs Licensing Agreement with SIMCERE PHARMA (02096) for New Indications of VV116

Stock News
·
Dec 03, 2025

BRIEF-Simcere Pharmaceutical Obtains Exclusive Rights For RSV And HMPV Treatment

Reuters
·
Dec 03, 2025

Simcere Pharmaceutical - Obtains Exclusive Rights for Rsv and Hmpv Treatment

THOMSON REUTERS
·
Dec 03, 2025

Vigonvita Life Sciences Signs License Agreement With Simcere Pharmaceutical for VV116 New Indications

Reuters
·
Dec 03, 2025

Simcere Pharma Grants 15.4 million RSUs Under Incentive Scheme; Shares Slip 4%

MT Newswires Live
·
Dec 02, 2025

Simcere (2096) Announces Grant of 15.4 Million RSUs under 2021 RSU Scheme

Bulletin Express
·
Dec 01, 2025

SIMCERE PHARMA (02096) Grants a Total of 15.4081 Million Restricted Share Units

Stock News
·
Dec 01, 2025

China Post Securities: PROTAC Achieves "0-1" Breakthrough, Sees Potential in Oral Autoimmune Therapies

Stock News
·
Nov 24, 2025

Riding the Hong Kong Stock Rally: Bull Market Dawns in the East 2026 – 10th Zhitong Finance Capital Markets Annual Conference Invites You to a Capital Feast

Stock News
·
Nov 18, 2025

Simcere's Il-2 Mutant Fusion Protein Sim0278 Entered Phase Ii Clinical Trial Stage

THOMSON REUTERS
·
Nov 15, 2025

Simcere (SEHK:2096) Valuation Spotlight After SIM0278 Advances to Phase II Trials for Atopic Dermatitis

Simply Wall St.
·
Nov 14, 2025

HK Stock Movement | SIMCERE PHARMA (02096) Rises Nearly 6% as IL-2 Mutant Fusion Protein SIM0278 Enters Phase II Clinical Trial

Stock News
·
Nov 13, 2025

Simcere Announces Phase II Clinical Trial Launch for SIM0278 in Atopic Dermatitis

Reuters
·
Nov 11, 2025

Simcere Launches Phase II Trial of SIM0278 for Moderate-to-Severe Atopic Dermatitis

Reuters
·
Nov 10, 2025

Simcere's Il-2 Mutant Fusion Protein Sim0278 Entered Phase Ii Clinical Trial Stage

THOMSON REUTERS
·
Nov 10, 2025

Simcere Pharmaceutical (02096) Announces October 2025 Monthly Return

Bulletin Express
·
Nov 05, 2025

Global Market Insights: 3 Stocks That May Be Trading Below Estimated Value

Simply Wall St.
·
Nov 04, 2025